CA2035177C - Mutants de la lipoproteine-lipase - Google Patents

Mutants de la lipoproteine-lipase Download PDF

Info

Publication number: CA2035177C
Authority: CA; Canada
Prior art keywords: dna; lpl; probe; codon; exon
Prior art date: 1991-01-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2035177

Other languages

English (en)

Other versions

CA2035177A1 (fr

Inventor

Michael R. Hayden

Howard E. Henderson

Yuanhong Ma

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of British Columbia

Original Assignee

University of British Columbia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-29

Filing date

1991-01-29

Publication date

2003-01-21

1991-01-29 Application filed by University of British Columbia filed Critical University of British Columbia

1991-01-29 Priority to CA 2035177 priority Critical patent/CA2035177C/fr

1992-07-30 Publication of CA2035177A1 publication Critical patent/CA2035177A1/fr

2003-01-21 Application granted granted Critical

2003-01-21 Publication of CA2035177C publication Critical patent/CA2035177C/fr

2011-01-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010013563 Lipoprotein Lipase Proteins 0.000 title abstract description 36
102100022119 Lipoprotein lipase Human genes 0.000 title 1
230000035772 mutation Effects 0.000 claims abstract description 59
238000006467 substitution reaction Methods 0.000 claims abstract description 20
238000000034 method Methods 0.000 claims abstract description 16
238000012216 screening Methods 0.000 claims abstract description 13
108020005187 Oligonucleotide Probes Proteins 0.000 claims abstract description 11
239000002751 oligonucleotide probe Substances 0.000 claims abstract description 11
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 9
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 9
235000009582 asparagine Nutrition 0.000 claims abstract description 9
229960001230 asparagine Drugs 0.000 claims abstract description 9
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 8
108020004414 DNA Proteins 0.000 claims description 53
108700028369 Alleles Proteins 0.000 claims description 36
239000000523 sample Substances 0.000 claims description 25
108091033380 Coding strand Proteins 0.000 claims description 19
108020004705 Codon Proteins 0.000 claims description 18
230000000295 complement effect Effects 0.000 claims description 18
238000009396 hybridization Methods 0.000 claims description 15
101100455036 Homo sapiens LPL gene Proteins 0.000 claims description 10
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
101710163270 Nuclease Proteins 0.000 claims description 7
239000002773 nucleotide Substances 0.000 claims description 7
125000003729 nucleotide group Chemical group 0.000 claims description 7
239000013612 plasmid Substances 0.000 claims description 7
239000012634 fragment Substances 0.000 claims description 6
108091034117 Oligonucleotide Proteins 0.000 claims description 5
230000003321 amplification Effects 0.000 claims description 5
238000003199 nucleic acid amplification method Methods 0.000 claims description 5
230000002285 radioactive effect Effects 0.000 claims 1
201000011110 familial lipoprotein lipase deficiency Diseases 0.000 abstract description 25
101000619884 Homo sapiens Lipoprotein lipase Proteins 0.000 abstract description 10
108090000623 proteins and genes Proteins 0.000 abstract description 10
102000045312 human LPL Human genes 0.000 abstract description 7
239000000969 carrier Substances 0.000 abstract description 6
125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 3
102000043296 Lipoprotein lipases Human genes 0.000 abstract 2
102000017055 Lipoprotein Lipase Human genes 0.000 description 29
210000001072 colon Anatomy 0.000 description 13
230000007812 deficiency Effects 0.000 description 11
102000054766 genetic haplotypes Human genes 0.000 description 11
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 10
101150062900 lpl gene Proteins 0.000 description 9
210000003050 axon Anatomy 0.000 description 8
238000004458 analytical method Methods 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
108090001060 Lipase Proteins 0.000 description 6
108700024394 Exon Proteins 0.000 description 5
108010010234 HDL Lipoproteins Proteins 0.000 description 5
102000015779 HDL Lipoproteins Human genes 0.000 description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
239000000872 buffer Substances 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
238000012360 testing method Methods 0.000 description 5
102000004882 Lipase Human genes 0.000 description 4
239000004367 Lipase Substances 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000029087 digestion Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000019421 lipase Nutrition 0.000 description 4
239000004677 Nylon Substances 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
238000001514 detection method Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000444 normolipidemic effect Effects 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
239000013598 vector Substances 0.000 description 3
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
108010004103 Chylomicrons Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
208000026758 coronary atherosclerosis Diseases 0.000 description 2
230000002950 deficient Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000002028 premature Effects 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
244000292411 Excoecaria agallocha Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
102000019267 Hepatic lipases Human genes 0.000 description 1
108050006747 Hepatic lipases Proteins 0.000 description 1
101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
206010024626 Lipoprotein deficiency Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
240000008881 Oenanthe javanica Species 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
108010079652 TCGA-specific type II deoxyribonucleases Proteins 0.000 description 1
206010060749 Type I hyperlipidaemia Diseases 0.000 description 1
206010048214 Xanthoma Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000004075 alteration Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
102000045903 human LPA Human genes 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000037434 nonsense mutation Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229910052704 radon Inorganic materials 0.000 description 1
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000007704 transition Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
125000005457 triglyceride group Chemical group 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA 2035177 1991-01-29 1991-01-29 Mutants de la lipoproteine-lipase Expired - Lifetime CA2035177C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2035177 CA2035177C (fr)	1991-01-29	1991-01-29	Mutants de la lipoproteine-lipase

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2035177 CA2035177C (fr)	1991-01-29	1991-01-29	Mutants de la lipoproteine-lipase

Publications (2)

Publication Number	Publication Date
CA2035177A1 CA2035177A1 (fr)	1992-07-30
CA2035177C true CA2035177C (fr)	2003-01-21

Family

ID=4146904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2035177 Expired - Lifetime CA2035177C (fr)	1991-01-29	1991-01-29	Mutants de la lipoproteine-lipase

Country Status (1)

Country	Link
CA (1)	CA2035177C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5658729A (en) *	1994-10-11	1997-08-19	The University Of British Columbia	Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
CN1297923A (zh) *	1999-11-29	2001-06-06	上海博容基因开发有限公司	一种新的多肽——人含细胞色素c结构域的脂蛋白105和编码这种多肽的多核苷酸

1991
- 1991-01-29 CA CA 2035177 patent/CA2035177C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2035177A1 (fr)	1992-07-30

Legal Events

Date	Code	Title	Description
1997-12-22	EEER	Examination request
2011-01-29	MKEX	Expiry

Publication	Publication Date	Title
Ozelius et al.	1988	Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism
Yoo et al.	1993	Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene
Handschug et al.	2001	Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene
Emi et al.	1990	Missense mutation (Gly----Glu188) of human lipoprotein lipase imparting functional deficiency.
Henderson et al.	1991	Amino acid substitution (Ile194----Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin.
Tsipouras et al.	1984	Molecular heterogeneity in the mild autosomal dominant forms of osteogenesis imperfecta
Ameis et al.	1991	Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene.
Gehrisch	1999	Common mutations of the lipoprotein lipase gene and their clinical significance
Zhang et al.	1995	Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease
Mendis et al.	1990	Genetic variation in the cholesteryl ester transfer protein and apolipoprotein AI genes and its relation to coronary heart disease in a Sri Lankan population
Ma et al.	1992	Two naturally occurring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase. In vivo evidence that aspartic acid 156 is essential for catalysis.
Ma et al.	1992	A missense mutation (Asp250→ Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries
Kappler et al.	1992	Late‐onset metachromatic leukodystrophy: molecular pathology in two siblings
CA2035177C (fr)	2003-01-21	Mutants de la lipoproteine-lipase
Gregor et al.	2002	Molecular study of the hydroxymethlybilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria
US6046009A (en)	2000-04-04	Diagnosis and treatment of glaucoma
Jacobsen et al.	1999	Mutational analysis of phospholipase A2A: a positional candidate susceptibility gene for bipolar disorder
Wood et al.	1993	Support for founder effect for two lipoprotein lipase (LPL) gene mutations in French Canadians by analysis of GT microsatellites flanking the LPL gene
US20040101863A1 (en)	2004-05-27	Method of detecting lipid metabolic errors
Pisciotta et al.	2002	A “de novo” mutation of the LDL-receptor gene as the cause of familial hypercholesterolemia
Yamakawa et al.	1988	Taq I polymorphism in the LDL receptor gene and a Taq I 1.5-kb band associated with familial hypercholesterolemia
Hattori et al.	1999	Identification of recurrent and novel mutations in the LDL receptor gene in Japanese familial hypercholesterolemia
Schuster et al.	1991	Use of DNA haplotype analysis in diagnosis of familial hypercholesterolaemia in 31 German families.
Bijvoet et al.	1996	Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250→ Asn; Ser251→ Cys) resulting in lipoprotein lipase (LPL) deficiency
Miller et al.	1997	Alternative splicing in lecithin: cholesterol acyltransferase mRNA: an evolutionary paradigm in humans and great apes